Advanced therapies in haematological disease
The Terapias Avanzadas en Oncohematología (Advanced Therapies in Oncohaematology) group from the Instituto de Investigación Sanitaria at the Hospital de La Princesa has a mission to promote clinical, epidemiological and translational research in haematological malignancies.
The group’s scope is broad, reflecting the heterogeneous nature of each of its members’ interests, ranging from genetic studies to commitment to new drug development.
The group has a differential interest in:
- Epidemiological studies in chronic myeloid leukaemia.
- Study of the efficacy and safety of new drugs in haematological malignancies.
- Immunological and genetic studies in haematological malignancies.
- Analysis of conditioning regimes in bone marrow transplantation (BMT).
- Analysis of infectious complications in BMT.
Over the past five years, our clinical research has focused on two fields. The first, within the European Leukaemia Network EUTOS, in epidemiological studies and recommendations for good clinical practice. Secondly, within the Spanish CML group (GELMC), to promote clinical research in this group. A multi-centre clinical trial is currently underway and another is awaiting approval. We have built a mobile app for IOS, Windows and Android for information exchange between GELMC members.
On a local level, our goal is to establish common projects that could cover all haematological malignancies treated in our group. The plan is thus to establish studies on quality of life, comorbidities and pharmacology.
Team members
|
Group leader: Juan Luis Steegmann Olmedillas Hospital Universitario La Princesa |
Other team members. Hospital Universitario La Princesa:
|
García-Gutiérrez V, Martinez-Trillos A, Lopez Lorenzo JL, Bautista G, Martin Mateos ML, Alvarez-Larrán A, Iglesias Pérez A, Romo Collado A, Fernandez A, Portero A, Cuevas B, Ruiz C, Romero E, Ortega F, Mata I, Tallón J, García Garay Mdel C, Ramirez Sánchez MJ, de Las Heras N, Giraldo P, Bobillo S, Guinea JM, Deben G, Valencia S, Sebrango A, Boqué C, Maestro B, Steegmann JL. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program. Am. J. Hematol. 2015. 90: 429-433. FI: 3.798(Q1). PMID: 25683327. DOI: 10.1002/ajh.23973.
García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Suñol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez López J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Peñarrubia MJ, Requena MJ, Fernández Valle Mdel C, Calle C, Paz Coll A, Hernández-Rivas JÁ, Franco Osorio R, Cano P, Tallón Pérez D, Fernández de la Mata M, Garrido PL, Steegmann JL. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?. Am. J. Hematol. 2014. 89: 206-211. FI: 3.798(Q1). PMID: 25059397. DOI: 10.1002/ajh.23816.
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014. 123: 494-500. FI: 10.452(Q1). PMID: 24311723. DOI: 10.1182/blood-2013-06-511592.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013. 122: 872-884. FI: 9.775(Q1). PMID: 23803709. DOI: 10.1182/blood-2013-05-501569.
Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013. 27: 2016-2022. FI: 9.379(Q1). PMID: 23752173. DOI: 10.1038/leu.2013.171.
